Department of Endocrinology and Metabolism, St. Paul's Hospital, Vancouver, British Columbia, Canada; University of British Columbia, Vancouver, British Columbia, Canada.
McMaster University, Hamilton, Ontario, Canada.
Can J Diabetes. 2015 Jun;39(3):216-20. doi: 10.1016/j.jcjd.2014.10.005. Epub 2015 Jan 23.
To assess the long-term effect of an Internet blood glucose monitoring system (IBGMS) on patients with type 1 diabetes mellitus and patients with type 2 diabetes.
In all, 1200 patients were offered to be taught to communicate with their endocrinologists using standardized glucose level reports by e-mail, and received feedback within 24 hours. The first 926 patients enrolled were reviewed consecutively from March 2011 to October 2013. Seventy-seven of these patients were excluded owing to lack of glycated hemoglobin (A1C) data. The remaining 849 patients consisted of 295 patients with type 1 diabetes and 554 patients with type 2 diabetes. Nonreporters are patients with no record of reporting (n=167), whereas the reporters had reported at least once (n=682). The A1C values were obtained at registration; follow-up values at 3-month intervals were recommended.
Reporter A1C decreased from 8.13%±1.34% to 7.74%±1.11% (p<0.0001). Reporters with type 1 diabetes dropped from 8.04%±1.23% to 7.72%±1.03% (n=238; p<0.0001). Reporters with type 2 diabetes dropped from 8.18%±1.40% to 7.75%±1.14% (n=444; p<0.0001) and were subdivided based on treatment: those on oral hypoglycemic agents declined from 7.96%±1.38% to 7.49%%±1.03% (p<0.0001), and those on insulin with or without oral hypoglycemic agents declined from 8.40%%±1.39% to 8.02%±1.20% (p<0.0001). The nonreporters did not show a significant change in A1C.
Initial and prolonged improvement was found in A1C levels for all reporters. The data support that numerous patients can be followed up effectively using the Internet for as long as 30 months.
评估 1 型和 2 型糖尿病患者使用互联网血糖监测系统(IBGMS)的长期效果。
共邀请 1200 名患者接受培训,通过电子邮件用标准化血糖报告与内分泌医生进行交流,并在 24 小时内获得反馈。2011 年 3 月至 2013 年 10 月连续纳入前 926 名患者。其中 77 例因糖化血红蛋白(A1C)数据缺失而被排除。其余 849 例患者包括 295 例 1 型糖尿病患者和 554 例 2 型糖尿病患者。无报告者是指无报告记录的患者(n=167),而报告者至少报告过一次(n=682)。A1C 值在登记时获得,建议每 3 个月随访一次。
报告者的 A1C 从 8.13%±1.34%降至 7.74%±1.11%(p<0.0001)。1 型糖尿病报告者从 8.04%±1.23%降至 7.72%±1.03%(n=238;p<0.0001)。2 型糖尿病报告者从 8.18%±1.40%降至 7.75%±1.14%(n=444;p<0.0001),并根据治疗进行了细分:口服降糖药组从 7.96%±1.38%降至 7.49%±1.03%(p<0.0001),胰岛素加或不加口服降糖药组从 8.40%±1.39%降至 8.02%±1.20%(p<0.0001)。无报告者的 A1C 无显著变化。
所有报告者的 A1C 水平均有初始和持续改善。数据支持使用互联网对多达 30 个月的患者进行有效随访。